Aurinia Pharmaceuticals Inc. AUPH

AUPH Company Overview

Aurinia Pharmaceuticals Inc. is a Canada-based biopharmaceutical company focused on developing and commercializing therapies for autoimmune and kidney-related diseases. The company operates primarily within the biotechnology and specialty pharmaceuticals industries, with its commercial focus centered on nephrology and immunology. Aurinia’s principal revenue driver is LUPKYNIS (voclosporin), an oral calcineurin inhibitor approved in the United States, Europe, and certain other jurisdictions for the treatment of adult patients with active lupus nephritis, a serious kidney manifestation of systemic lupus erythematosus.

The company traces its origins to Aurinia Pharmaceuticals Inc.’s merger-related restructuring activities involving legacy entities including Aspreva Pharmaceuticals and Isotechnika Pharma Inc. Aurinia evolved from a development-stage biotechnology company into a commercial-stage organization following U.S. Food and Drug Administration approval of LUPKYNIS in 2021. Its strategic positioning is based on specialization in autoimmune kidney disease, intellectual property protection surrounding voclosporin, and established relationships with nephrologists and rheumatologists treating lupus nephritis patients.